• Molecular NameFoscarnet
  • SynonymN/A
  • Weight122.981
  • Drugbank_IDDB00529
  • ACS_NO63585-09-1
  • Show 3D model
  • LogP (experiment)0.0
  • LogP (predicted, AB/LogP v2.0)-2.63
  • pka0.5, 3.4, 7.3
  • LogD (pH=7, predicted)-7.78
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)0.9
  • LogSw (predicted, AB/LogsW2.0)440.13
  • Sw (mg/ml) (predicted, ACD/Labs)798.07
  • No.of HBond Donors3
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds1
  • TPSA104.64
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyThe conjugate base of the chemical compound with the formula HO2CPO3H2.
  • Absorption_value18.0
  • Absorption (description)Foscarnet is poorly absorbed after oral administration
  • Caco_20.0
  • Bioavailability9.0
  • Protein binding15.5
  • Volume of distribution (VD)0.35 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmNot metabolised to a great extent.
  • Half life5.7 h
  • ExcretionThe drug is excreted mostly unchanged in the urine by glomerular filtration and tubular secretion, and is also cleared by uptake into bones (14 to 22%). It is removed by haemodialysis.
  • Urinary Excretion95
  • Clerance1.6 ml/min/kg
  • ToxicityRenal impairment is the major toxicity. Seizures related to alterations in plasma minerals and electrolytes have also been associated with foscarnet therapy.
  • LD50 (rat)LD50> 2000 mg/kg
  • LD50 (mouse)N/A